<SEC-DOCUMENT>0001193125-23-077853.txt : 20230323
<SEC-HEADER>0001193125-23-077853.hdr.sgml : 20230323
<ACCEPTANCE-DATETIME>20230323160554
ACCESSION NUMBER:		0001193125-23-077853
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230323
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230323
DATE AS OF CHANGE:		20230323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Equillium, Inc.
		CENTRAL INDEX KEY:			0001746466
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				821554746
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38692
		FILM NUMBER:		23756218

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 105
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 412-5302

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 105
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d471634d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eq="http://equilliumbio.com/20230323" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-03-23_to_2023-03-23">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-03-23_to_2023-03-23">0001746466</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="eq-20230323.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-03-23_to_2023-03-23"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001746466</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-23</xbrli:startDate> <xbrli:endDate>2023-03-23</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-03-23_to_2023-03-23">8-K</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt:datemonthdayyearen">March 23, 2023</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-03-23_to_2023-03-23">Equillium, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-03-23_to_2023-03-23">001-38692</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-03-23_to_2023-03-23">82-1554746</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-03-23_to_2023-03-23">2223 Avenida de la Playa</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-03-23_to_2023-03-23">Suite 105</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-03-23_to_2023-03-23">La Jolla</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-03-23_to_2023-03-23">92037</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-03-23_to_2023-03-23">(858)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-03-23_to_2023-03-23">412-5302</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-03-23_to_2023-03-23">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-03-23_to_2023-03-23">EQ</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-03-23_to_2023-03-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;2.02 Results of Operations and Financial Condition.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On March&#160;23, 2023, Equillium, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter and year ended December&#160;31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The information in this Item 2.02 of this Current Report on <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today&#8217;s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:97%;border:0;margin-left:auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d471634dex991.htm">Press Release dated March&#160;23, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table></div> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">EQUILLIUM, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date: March&#160;23, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Bruce D. Steel</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Bruce D. Steel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d471634dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Provides Corporate&nbsp;&amp; Clinical Development Updates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><I>$71.0&nbsp;million cash balance at the end of 2022 expected to provide cash runway into 2025 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><I>Acquired Bioniz Therapeutics, including two <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
clinical-stage assets, EQ101 and EQ102, and proprietary product discovery platform </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><I>Initiated Phase 2 clinical study of EQ101 in alopecia
areata and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical study of EQ102 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><I>Entered
into strategic partnership and an option and asset purchase agreement with Ono Pharmaceutical for the development and commercialization rights to itolizumab, including an upfront payment of $26.4&nbsp;million, development funding, and approximately
$139&nbsp;million<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> in potential option exercise and milestone payments </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>LA JOLLA, California,
March</B><B></B><B>&nbsp;23, 2023 &#150;</B> Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders
with high unmet medical need, today announced financial results for the fourth quarter and full year 2022 and provided corporate and clinical development updates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">&#147;Equillium achieved several significant objectives during 2022, and in the process transformed into a company with a newly diversified pipeline including two
wholly-owned, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> clinical-stage assets, a proprietary drug discovery platform and a strong balance sheet expected to fund our development programs through
multiple key milestones,&#148; said Bruce Steel, chief executive officer at Equillium. &#147;We acquired Bioniz Therapeutics in February last year expanding our pipeline with two multi-cytokine inhibitors, EQ101 and EQ102, that we have since
advanced into a Phase 2 clinical study in subjects with alopecia areata and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical study in healthy volunteers to be followed by patients with celiac
disease, respectively. We plan to announce data from both studies in the second half of this year. Based on the initiation of EQUATOR, our pivotal study of itolizumab in first-line acute graft-versus-host disease, and positive interim data from the
EQUALISE study of itolizumab in patients with lupus nephritis, we secured a strategic partnership with Ono Pharmaceutical under which they purchased an exclusive option to acquire our rights for the development and commercialization of itolizumab.
The partnership came with payments to Equillium totaling $38.6&nbsp;million during December 2022, funding of itolizumab research and development costs during the option period, and potential future option exercise and milestone payments totaling
approximately $139 million<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>. Based on our strong cash balance and significantly reduced operating burn resulting from the Ono partnership, we expect to be able to fund operations into 2025, and
potentially beyond if Ono exercises its option. We look forward to upcoming data from the EQ101 and EQ102 development programs and continuing to advance itolizumab under our Ono partnership.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>2022 Corporate Highlights: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Acquired Bioniz Therapeutics, adding a proprietary product discovery platform and significantly expanding the
company&#146;s pipeline of novel immunomodulatory drug candidates, including two <FONT STYLE="white-space:nowrap">first-in-class</FONT> clinical-stage assets: EQ101, a <FONT STYLE="white-space:nowrap">tri-specific</FONT> inhibitor of <FONT
STYLE="white-space:nowrap">IL-2,</FONT> <FONT STYLE="white-space:nowrap">IL-9</FONT> and <FONT STYLE="white-space:nowrap">IL-15,</FONT> and EQ102, a <FONT STYLE="white-space:nowrap">bi-specific</FONT> inhibitor of
<FONT STYLE="white-space:nowrap">IL-15</FONT> and <FONT STYLE="white-space:nowrap">IL-21.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Entered into an option and asset purchase agreement with Ono Pharmaceutical for the exclusive option to acquire our
development and commercialization rights to itolizumab. Equillium received an upfront payment of $26.4&nbsp;million and is also eligible to receive up to approximately $139 million<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> in option
exercise and payments for achieving certain development and commercialization milestones. Equillium will be responsible for conducting all research and development of itolizumab, which will be funded by Ono on a quarterly basis commencing
July&nbsp;1, 2022 through the option period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Appointed Barbara Troupin, M.D., to Equillium&#146;s board of directors. </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Calibri; " ALIGN="left">Option exercise payment is denominated in Japanese yen (5 billion) and subject to currency exchange rates at the time
of payment (U.S. dollar amount estimated above is based on the exchange rate as quoted by MUFG Bank, Ltd. on March&nbsp;16, 2023). R&amp;D funding and milestone payments are denominated in U.S. dollars. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>2022 Clinical Highlights: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Initiated a multicenter, Phase 2 open-label,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical study of EQ101 in adult subjects with at least 35% scalp hair loss due to alopecia areata. Approximately 30 subjects will be enrolled in the
study where they will be dosed intravenously once weekly for 24 weeks. Subcutaneous formulation development of EQ101 is ongoing and expected to be ready for subsequent clinical studies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Initiated a Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT>
randomized, double-blind, placebo-controlled clinical study of EQ102 administered subcutaneously in single ascending dose (SAD) and multiple ascending dose (MAD) cohorts in up to 64 healthy volunteers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Initiated EQUATOR, a pivotal Phase 3 randomized, double-blind clinical study of up to 200 patients to assess the efficacy
and safety of itolizumab versus placebo as a first-line therapy for acute graft-versus-host disease (aGVHD) in combination with corticosteroids. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Announced positive interim results from the Type B portion of the EQUALISE study of itolizumab in subjects with lupus
nephritis </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>Anticipated Upcoming Milestones: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">EQ101: Phase 2 clinical study in subjects with alopecia areata &#150; initial data anticipated in 2H 2023, topline data
anticipated in <FONT STYLE="white-space:nowrap">mid-2024</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">EQ102: Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in
healthy volunteers and subjects with celiac disease &#150; SAD/MAD data anticipated in 2H 2023, celiac disease patient data anticipated in 2024 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:10pt">Itolizumab: EQUALISE lupus nephritis topline data anticipated in 1H 2024, EQUATOR aGVHD interim review anticipated in
2024 </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>Fourth Quarter and Full Year 2022 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B><I>Revenue</I></B> for the fourth quarter and full year of 2022 was $15.8&nbsp;million and was derived from the company&#146;s asset purchase agreement with Ono.
There was no revenue recognized in the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B><I>Research and development (R&amp;D) expenses</I></B> for the fourth quarter of
2022 were $8.5&nbsp;million, compared with $7.5&nbsp;million for the same period in 2021. For the full year of 2022, R&amp;D expenses were $37.5&nbsp;million, compared with $26.4&nbsp;million for the full year of 2021. The year-over-year increase in
R&amp;D expenses was driven by <FONT STYLE="white-space:nowrap">start-up</FONT> costs related to our Phase 3 EQUATOR clinical study and to a lesser extent <FONT STYLE="white-space:nowrap">start-up</FONT> costs related to our EQ101 and EQ102 clinical
studies, an increase in <FONT STYLE="white-space:nowrap">non-clinical</FONT> research expenses and employee compensation and benefits, offset by a greater estimated Australian R&amp;D Tax Incentive benefit and lower costs associated with our other
itolizumab clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B><I>General and administrative (G&amp;A) expenses</I></B> for the fourth quarter of 2022 were $5.2&nbsp;million, compared with
$2.8&nbsp;million for the same period in 2021. For the full year of 2022, G&amp;A expenses were $17.2&nbsp;million, compared with $11.4&nbsp;million for the full year of 2021. The year-over-year increase was primarily driven by increased legal
expenses related to business development activities, greater headcount and consulting expenses, the <FONT STYLE="white-space:nowrap">non-cash</FONT> <FONT STYLE="white-space:nowrap">write-off</FONT> of issuance costs related to certain financings
where future proceeds were unlikely, and greater overhead expenses. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B><I>Net Income</I></B> for the fourth quarter of 2022 was $2.8&nbsp;million, or $0.08 per basic share and diluted
share, compared with a net loss of $10.6&nbsp;million, or $(0.36) per basic and diluted share for the same period in 2021. Net loss for the full year of 2022 was $62.4&nbsp;million, or $(1.85) per basic and diluted share, compared with a net loss of
$39.1&nbsp;million, or $(1.36) per basic and diluted share for the full year of 2021. The increase in net loss for the full year of 2022 compared to the full year of 2021 was driven primarily by greater operating expenses, including a <FONT
STYLE="white-space:nowrap">non-cash</FONT> <FONT STYLE="white-space:nowrap">in-process</FONT> R&amp;D expense related to the acquisition of Bioniz in 2022, partially offset by revenue recognized in the fourth quarter of 2022 related to the Ono
partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B><I>Cash, cash equivalents and short-term investments</I></B> totaled $71.0&nbsp;million as of December&nbsp;31, 2022, compared to
$80.7&nbsp;million as of December&nbsp;31, 2021. Cash provided by operating activities in the fourth quarter of 2022 was $27.7&nbsp;million. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Adjusted Cash Used in Operations in the fourth quarter of
2022 was $5.2&nbsp;million, which excludes the <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment from Ono and is further adjusted by incorporating only the development funding received from Ono pertaining to itolizumab development
costs in the fourth quarter of 2022. Equillium believes that its cash, cash equivalents and short-term investments will be sufficient to fund its currently planned operations into 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures (Unaudited) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">In this release, we use the metric of Adjusted Cash Used in Operations, which is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure and is not
calculated in accordance with generally accepted accounting principles in the United States (GAAP). Adjusted Cash Used in Operations reflects adjustments to net cash provided by (used in) operating activities to exclude the effects of any <FONT
STYLE="white-space:nowrap">one-time</FONT> payments from Ono and quarterly development funding received in but unrelated to the period, and add any quarterly development funding amounts receivable related to development costs in the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">We believe Adjusted Cash Used in Operations is a useful metric to investors as a supplement to GAAP measures in the assessment of our operating cash burn because it
removes the effects of any <FONT STYLE="white-space:nowrap">one-time</FONT> payments, which are not indicative of our ongoing cash flow from operations, and it provides better matching of the timing of itolizumab development funding payments with
the associated itolizumab development costs. However, Adjusted Cash Used in Operations may fluctuate significantly from quarter to quarter, and the estimate provided for one quarter should not be assumed to be representative of other quarters. In
addition, this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure may be different from <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures used by other companies, even when the same or similarly titled terms are
used to identify such measures, limiting their usefulness for comparative purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">This <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure is
not meant to be considered in isolation or used as a substitute for net cash provided by (used in) operating activities reported in accordance with GAAP; should be considered in conjunction with our financial information presented in accordance with
GAAP; has no standardized meaning prescribed by GAAP; is unaudited; and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that we may exclude for
purposes of this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, and we may in the future cease to exclude items that we have historically excluded for purposes of this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial
measure. Likewise, we may determine to modify the nature of adjustments to arrive at this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. Because of the <FONT STYLE="white-space:nowrap">non-standardized</FONT> definitions of <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures, the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure as used by us in this press release and the accompanying reconciliation table has limits in its usefulness to
investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. Reconciliations of this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure to the most directly comparable GAAP financial measure are presented in the table at the
end of this release. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>About Multi-Cytokine Platform and EQ101 &amp; EQ102 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Our proprietary <U><FONT STYLE="white-space:nowrap">multi-cytokine</FONT> platform</U> generates rationally designed composite peptides that selectively block key
cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving <FONT STYLE="white-space:nowrap">non-pathogenic</FONT> signaling. This approach is expected to avoid the broad immuno-suppression and <FONT
STYLE="white-space:nowrap">off-target</FONT> safety liabilities that may be associated with other therapeutic classes, such as Janus kinase inhibitors. Many immune-mediated diseases are driven by the same combination of dysregulated cytokines, and
we believe identifying the key cytokines for these diseases will allow us to target and develop customized treatment strategies for multiple autoimmune and inflammatory diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Current platform assets include EQ101, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> selective, <FONT
STYLE="white-space:nowrap">tri-specific</FONT> inhibitor of <FONT STYLE="white-space:nowrap">IL-2,</FONT> <FONT STYLE="white-space:nowrap">IL-9</FONT> and <FONT STYLE="white-space:nowrap">IL-15,</FONT> and EQ102, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class,</FONT></FONT> selective, <FONT STYLE="white-space:nowrap">bi-specific</FONT> inhibitor of <FONT STYLE="white-space:nowrap">IL-15</FONT> and <FONT STYLE="white-space:nowrap">IL-21.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>About Itolizumab </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><U>Itolizumab</U> is a clinical-stage, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">anti-CD6</FONT> monoclonal antibody that selectively targets the <FONT STYLE="white-space:nowrap">CD6-ALCAM</FONT> signaling
pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. This pathway plays a central role in modulating the activity and trafficking of T cells that
drive a number of immuno-inflammatory diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>About Equillium </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and
inflammatory disorders with high unmet medical need. The company&#146;s pipeline consists of the following novel <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunomodulatory assets targeting
immuno-inflammatory pathways. EQ101: a <FONT STYLE="white-space:nowrap">tri-specific</FONT> cytokine inhibitor that selectively targets <FONT STYLE="white-space:nowrap">IL-2,</FONT> <FONT STYLE="white-space:nowrap">IL-9,</FONT> and <FONT
STYLE="white-space:nowrap">IL-15;</FONT> currently under evaluation in a Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical study of patients with alopecia areata. EQ102: a <FONT
STYLE="white-space:nowrap">bi-specific</FONT> cytokine inhibitor that selectively targets <FONT STYLE="white-space:nowrap">IL-15</FONT> and <FONT STYLE="white-space:nowrap">IL-21;</FONT> currently under evaluation in a Phase 1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical study to include healthy volunteers and celiac disease patients. Itolizumab: a monoclonal antibody that targets the
<FONT STYLE="white-space:nowrap">CD6-ALCAM</FONT> signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and
a Phase 1b clinical study of patients with lupus/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd. for the
development and commercialization of itolizumab under an option and asset purchase agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">For more information, visit&nbsp;<U>www.equilliumbio.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><I>Statements contained in this press release
regarding matters that are not historical facts are &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as
&#147;anticipate&#148;, &#147;believe&#148;, &#147;could&#148;, &#147;continue&#148;, &#147;expect&#148;, &#147;estimate&#148;, &#147;may&#148;, &#147;plan&#148;, &#147;outlook&#148;, &#147;future&#148; and &#147;project&#148; and other similar
expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium&#146;s control, actual results may
differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding&nbsp;Equillium&#146;s plans and expected timing for developing EQ101 and EQ102 including the
expected timing of initiating, completing and announcing further results from Phase 2 and Phase 1 clinical studies, respectively, the potential for any of Equillium&#146;s ongoing or planned clinical studies to show safety or efficacy, the benefit
of treating patients with aGVHD or lupus/lupus nephritis with itolizumab, Equillium&#146;s plans and expected timing for developing itolizumab including the expected timing of initiating, completing and announcing further results from the EQUATE,
EQUATOR and EQUALISE studies, Equillium&#146;s anticipated timing of regulatory review and feedback, the potential benefits and risks of the transactions contemplated by the asset purchase agreement entered into between Equillium and Ono, including
the possibility that Ono does not exercise the </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><I>
option, Equillium receives no further payments under the asset purchase agreement other than those already received, the fluctuation of the foreign exchange rate, Equillium&#146;s cash runway,
and Equillium&#146;s plans and expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium&#146;s ability
to execute its plans and strategies; risks related to performing clinical studies; the risk that interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as
patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data
therefrom;&nbsp;the risk that&nbsp;studies will&nbsp;not be&nbsp;completed&nbsp;as planned; Equillium&#146;s plans and product development, including the initiation and completion of clinical studies and the reporting of data therefrom; whether the
results from clinical studies will validate and support the safety and efficacy of Equillium&#146;s product candidates; risks related to Ono&#146;s financial condition, willingness to continue to fund the development of itolizumab, and decision to
exercise its option to purchase itolizumab or terminate the asset purchase agreement; changes in the competitive landscape; uncertainties related to Equillium&#146;s capital requirements; and having to use cash in ways or on timing other than
expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption &#147;Risk Factors&#148; and elsewhere in Equillium&#146;s filings and reports, which may be accessed
for free by visiting the Securities and Exchange Commission&#146;s website at and on Equillium&#146;s website under the heading &#147;Investors.&#148; Investors should take such risks into account and should not rely on forward-looking statements
when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made, except as required by law. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>Investor&nbsp;&amp; Media Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Equillium, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Michael Moore </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Vice President, Investor Relations Officer&nbsp;&amp; Head of Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">619-302-4431</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><U>ir@equilliumbio.com </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Equillium, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>(unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">71,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">80,711</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">2,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">3,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">3,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">1,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">1,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">78,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">85,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Accounts payable and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">17,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> 8,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Current portion of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">14,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">32,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">8,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Long-term deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">10,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">4,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">9,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">46,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">18,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">31,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">66,505</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">78,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">85,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Equillium, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Condensed Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>(In thousands, except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>Three Months Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">15,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">15,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">8,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">7,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">37,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">26,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">23,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">5,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">2,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">17,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">11,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">13,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">10,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">77,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">37,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">2,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(10,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(62,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(37,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(1,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">2,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> (10,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> (62,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> (39,052</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Net income (loss) per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(0.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> (1.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> (1.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Weighted-average number of common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">34,366,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">29,411,242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">33,727,945</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">28,806,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g471634g94j84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">The table below presents the reconciliation of Adjusted Cash Used in Operations, which is a
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. See &#147;Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures (Unaudited)&#148; above for further information regarding the company&#146;s use of <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Equillium, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Reconciliation of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>(unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>Three Months Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Calibri; "><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri"><B>Adjusted Cash Used in Operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Net cash provided by (used in) operating activities (GAAP)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; "> 27,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(10,133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(8,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(32,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Ono upfront payment<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(26,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(26,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Cash received for development funding from Ono unrelated to the period<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(9,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(3,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Receivable for development funding from Ono in the
period<SUP STYLE="font-size:75%; vertical-align:top">3</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">2,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">2,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Calibri">Adjusted Cash Used in Operations <FONT STYLE="white-space:nowrap">(Non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(5,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(10,133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(35,492</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Calibri; ">(32,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Calibri; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Calibri; " ALIGN="left">We received a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $26.4&nbsp;million from Ono in exchange for
the option to acquire our rights for the development and commercialization of itolizumab. In accordance with GAAP, it was included in net cash provided by (used in) operating activities in the period received. We have excluded receipt of the upfront
payment from Adjusted Cash Used in Operations. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Calibri; " ALIGN="left">During the three months ended December&nbsp;31, 2022, the company received $9.4&nbsp;million in cash for development
funding from Ono, which included $6.2&nbsp;million related to itolizumab development costs for the third quarter of 2022 and $3.2&nbsp;million as an advance payment for itolizumab development costs for the first quarter of 2023. For the three months
ended December&nbsp;31, 2022, we have excluded such $9.4&nbsp;million of cash received for itolizumab development funding since it was unrelated to itolizumab development costs in the period. For the year ended December&nbsp;31, 2022, we have
excluded the $3.2&nbsp;million of cash received as an advance payment for itolizumab development costs for the first quarter of 2023 since it was unrelated to itolizumab development costs in the period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Calibri; " ALIGN="left">This reflects an unbilled receivable amount as of December&nbsp;31, 2022, related to itolizumab development costs in
the fourth quarter of 2022. We add this amount as a timing adjustment since the amount relates to development costs in the three months ended December&nbsp;31, 2022. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>eq-20230323.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/23/2023 10:46:23 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:eq="http://equilliumbio.com/20230323"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://equilliumbio.com/20230323"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eq-20230323_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eq-20230323_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>eq-20230323_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/23/2023 10:46:23 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>eq-20230323_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/23/2023 10:46:23 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eq-20230323.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g471634g94j84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g471634g94j84.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MT60GVK>-9/2<947VFK+Y23<7\I%J2ZIQ:Z/_ #5U^);K4H* "@ H * "@ H
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M_P#/N"C9SDNMKZWTLN8JW.N>._#*?;O$&G:3J^CQE?MEQH9GCN[*,D S&&?
MEC7J<+CU=1S6E/!Y/CG[' UZV%Q3_AQQ"BX3:VCS1^%O97^29A5S'B/*8_6,
MSPN&QN!C;VL\(YQJT8[.?)/XHQW=EZR6YZ38W=O?6EO>VDJSVMU$D\$J]'CD
M4,IP>0<'!!Y!!!Y%>%4I3H5)TJD7"I2DXRB^C3LT?5T*U+$T:5>A-3HUHJ<)
M+9Q:NGY>FZV9:J#4* /)OBE>VT?_  B^EZA/]GTF_P!7-QJKX=@;/3OL[/&R
MQJ696-R. "<JI[5]'P]1J/\ M#$4(<V)H4.6BM%^\J\R33=DFE%[O:Y\7QAB
M*,/['P>*J>RP6)Q//B'9O]U0Y&XM13;3<UHD]4GT-I?B/X'C58TUF)$151$6
MROU5$4!555%I@*   !Z5R/(<WNV\))OJW.GO_P"!GH1XKX>@E&./C&,4DDJ5
M9)):))*GHDBIJ'CSP%J-A=Z?<ZS$\%W;RV\BFSOS\LB%0P!M/O*2&![%01TK
M2CDV<X>K2K4\)*,Z,HRB^>GO%W_G^3\C'%<2<-XO#5\+5Q\94Z\)0DG2K;-6
M_P"?>ZW3Z-'-^']?NK/X4:C>)(S7&DI?:9:S\A@&EBBM9%/4>6EXFWT$8':N
M_&X*G4XDH4G'EAB73JSCT^%N:_[><'?S9Y.5YG6P_!>*Q$9-U,"JU"G+K\2C
M3:_PJI&W;E1Z)X/TB#1/#FE6<*A6:TANKI_XIKNYC2:>5VZL=S;03T5%':O#
MS/$SQ>.Q%63T4W""Z1A!N,8I=$DK^K;/J<BP-/+\JP="FK-TXU*DNLJE1*4Y
M-]7=V5^B2Z'3=/;'X8Q7 >OMY6/-)HET3XE6#VH\NW\5Z7=I?0KPCWVG S)<
M[1QYA14!/J[D\L:]Z$OK60UE4UGEM:#IOJJ=7W7"_9/5+R2Z'R4X++^+,,Z/
MNTLYP]55HK9UJ"YE4MW<;)OSD]VR7P9_R,OQ#_[#=G^D%Q2S7_<,C_Z\5/\
MTM%9!IFW%'3_ &NE_P"FY'HU>$?5GG+\?%2'_L3V_2_:O=C_ ,DY+RQR_P#3
M1\K+_DLJ?EEC_P#3XW0?^2B^./\ KST/_P!)DHQG_(BRC_KYB/\ TLG+/^2I
MXA_Z]83_ --A?_\ )4= _P"Q9U#_ -'7-%#_ ))[&_\ 872_])0\3_R6.6?]
M@%;_ -+F+\0O]=X*_P"QPTW^3T9)\.:_]@57]!\3_'D'_8SP_P#[<:7Q'_Y$
MKQ!_UZP_^EMM6&1?\C; _P"-_P#I$CIXJ_Y)[-/^O<?_ $Y Q_&7'PQF[?\
M$HT7VZ26%=.5?\E!3\J];\JAQ9]IP?5Z?[-A?_2J)Z#IW_(/L/\ KRM?_1$=
M>+6_C5?\<O\ TIGT^%_W;#_]>J?_ *2A-2XTW4.W^@W?M_R[R48?2O1Z6J0_
M]*0L7_NN)_Z]5/\ TAGC"W4MI\%H/)8J]Q ;+<."$NM9DBEY'8Q%U_X%7U3I
MQJ<634E>-.?/;SA04E]S2?R/@56G0\/Z?LWRRJP]E==%4Q3A+[XMKYGLNEV4
M.G:;86-NH2&TL[>!% P,1Q*I/'=FRQ/<DGO7RU>K*M7K5IN\JDY2?S;?X;(^
M]P>'AA,)AL-22C3H4X0BEVC%+[WN_,R?&-C%?^%M=MI5#!=-N;B/(!V36D;7
M,+CT*R1+S]?6NG*ZTL/F&#J0=K581?\ AFU"2^:;1Q9[AX8K)\QI36BH5)Q\
MI4XN<6NS4HHR?AK9Q6?@W26C4![U9KZ=N[RSSR %CW*Q)$GT05TY]5E4S7%)
MO2BU3BNT816B^=W\SAX2H0H9#@7%6E74JTWU<IR>K\U%1C\CN)8HYXI()4#Q
M31O%*C#*O'(I1T8>A4D'ZUY$9.$HRB^646FFNC6J?R:/HIPC4A*G.*E":<91
M>SBU9IKLT['G_P ,&=- O=/9BR:/K^K:9 2<XAB>*90#Z!KAJ]O/TGC*-=+E
M>*PU&M+_ !-.+_\ 23YCA"4HY;B,*W>. QN)P\/\,)1FE\N=GH]>&?4A0!YK
M\2+6>&WT/Q';PFY/AG5$O+FW"AB^GS&);L[3V7RHL^BDL>%KW<BJ0E/%X"<_
M9K'T73A+:U6-W#\W;SLNI\IQ51J4Z67YK2I^U>3XA5:D$KWHRLJNGERQOV5W
MLCM+";2]2L[>_L5M+BTN8UEAE2*(@J1RK#;\DBG*LIP5(((R*\FM'$8:K.C6
MYX5*;M*+;W7YI[IK1K5'T&&G@\90I8G#*G4HU8J49*,;6[;:-;-/5--/5$TZ
MV%I#+<7"6<%O C22S2QPI'%&HRS.[* H ]:F#K3E&G3<Y3D[1BFVV^B21I4C
MAJ%.=6K&G2ITTY2E)148I;MMJR2,+5;6R\4^%+^VTJ6"6VU6PD-E-" D+S*=
M\!(VKM_TB)%;(!&"",BNO#5*N79C1J8B,HU,+47/&7Q);277[+=K:,\[&T,/
MG&2XFE@YPE2QE&7LI1TBY;P?2UIQ2=U=6L]BIX%UV/5]$M[:4^3JNCQIINJ6
M4GRSP3V@\@2-&>=DBQ@[L8W;EZJ:US?!RPF+G./O8;$MU:,U\,H3]ZR>UXWL
MUVL]F8<.9C'&Y?2I3_=XW Q5#$4GI.$Z:Y+N+UM)1NGM>ZW3.T. /0*,Y/
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M]S15>X\26?W]/T_5HQ_'8W+Z?<X'?[->"2,GV%P*R=3,Z.^'I8N*ZTINE/\
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J0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140685789539680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001746466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 23,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Equillium, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1554746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2223 Avenida de la Playa<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">412-5302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d471634d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eq-20230323.xsd" xlink:type="simple"/>
    <context id="duration_2023-03-23_to_2023-03-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746466</identifier>
        </entity>
        <period>
            <startDate>2023-03-23</startDate>
            <endDate>2023-03-23</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-03-23_to_2023-03-23">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-03-23_to_2023-03-23"
      id="Hidden_dei_EntityCentralIndexKey">0001746466</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-03-23_to_2023-03-23">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-03-23_to_2023-03-23">2023-03-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-03-23_to_2023-03-23">Equillium, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-03-23_to_2023-03-23">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-03-23_to_2023-03-23">001-38692</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-03-23_to_2023-03-23">82-1554746</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-03-23_to_2023-03-23">2223 Avenida de la Playa</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-03-23_to_2023-03-23">Suite 105</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-03-23_to_2023-03-23">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-03-23_to_2023-03-23">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-03-23_to_2023-03-23">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-03-23_to_2023-03-23">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-03-23_to_2023-03-23">412-5302</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-03-23_to_2023-03-23">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-03-23_to_2023-03-23">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-03-23_to_2023-03-23">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-03-23_to_2023-03-23">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-03-23_to_2023-03-23">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-03-23_to_2023-03-23">EQ</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-03-23_to_2023-03-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-03-23_to_2023-03-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-03-23_to_2023-03-23">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCVQBLUMSS!?P3:\?G7/T2O)@J_2;67-NR2Z6B1EZ:VO3VU;+A&L>,W.E4I[
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MD*24MLEXPQ,1,9@,B61D*MF>8;R5\P>H<>.\\ZVJY<4E9YF ^@W\+@9867^
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M<P:#TST ]Y=*V?<3M_<O/]V,_@-02P,$%     @ NH!W5I^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ NH!W5@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "Z@'=6D<FM;.X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "Z@'=6F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +J =U;+
M#Y8<>00  ,81   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "Z@'=6GZ ;\+$"  #B#   #0
M    @ &\#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +J =U:7BKL<P
M !,"   +              "  9@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M +J =U8<.&7J/P$  #P"   /              "  8$0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "Z@'=6)!Z;HJT   #X 0  &@
M@ 'M$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "Z
M@'=699!YDAD!  #/ P  $P              @ '2$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"   <%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d471634d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d471634d8k.htm">d471634d8k.htm</File>
    <File>d471634dex991.htm</File>
    <File>eq-20230323.xsd</File>
    <File>eq-20230323_lab.xml</File>
    <File>eq-20230323_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d471634d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d471634d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eq-20230323_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eq-20230323_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eq-20230323.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "eq",
   "nsuri": "http://equilliumbio.com/20230323",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d471634d8k.htm",
      "contextRef": "duration_2023-03-23_to_2023-03-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d471634d8k.htm",
      "contextRef": "duration_2023-03-23_to_2023-03-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://equilliumbio.com//20230323/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-077853-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-077853-xbrl.zip
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M#_H=[N4MKX^0EXHELS2"0O(T&&!>H_#7I^NVU6-]FN.N5-2U1BL$2LR%IUJ
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MGSO#VCWO,TENV!-I>7WJGNJVIQ#NCN?8IRGD^7S3O&]<D?;]Y7VC/1^<XH[
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M1^,EO_%E<K4TW^_[Y->U>?3=L+;3]=:+ )<<[:R9[9B51_VYQA6 ;64N"K)
MWHG  N<R3]J*,6<DDSNN=?EQ%.3:#(#%%[MEN6F2OM)Q$UC555.[)21&Y?JM
M\CIM6N]QU@77.;X)?JMO@HNT$(^D1&5GA?#_8M#_4\/%_P%02P,$%     @
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M&(XBXGZ,_%TX4G+R[- )W!R@._#P&&":&": YT(W%  %,2K3X'QZ@><-:\'
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M@-9G\A6AYS4D-H\/H9 8>6JN%M=WG1J,LU6&(DLLGHC%K8,'LADRVJA6)B1
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M22@ #8PP4Y>@8L=1U5/(0ELH->Y6 B#CW2@80<*EB4CFZJHZ/^P)I,""*7\
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MG!#K5I3:LG9WUZCE^&H+!]'7L+/LSF^/I'2M&%([+6NKM>0TM_6$5'O?:CR
M(O]\==/GUO>MA-13UKY*&*T?C%Z2_W1,(Z5V>_"Y'_BRZY[%.CQV;5E^YGII
M(IQUTUH;]<8:75.U4E!M-NKM]8CWK%JWKR_[*J%UA=,#X%.IK3X)_:*$5*F)
ME3!:H;;Z\CRJ?P@4-L*I\1L1P2:9GV*?5&QH;2JQ,0O2)$Y AW7]ZZ>AT3Y
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M.K$]R-&;=Q?O_X0O/U]].3_^?U!+ P04    " "Z@'=6_92P7$$#  !'"P
M#P   &5Q+3(P,C,P,S(S+GAS9+U6;6_;-A#^7J#_X:I/&S")DKT&C1"GZ)8&
M")!FA9L._5;0TMDA2I$*227QO]^1DAS%CCTG*1H8",V[Y^%S+SSZZ/U=)>$&
MC15:3:(L22- 5>A2J,4D:FS,;2%$]/[X]:NC-W$,)Z=G%Q##E7.US1F[O;U-
MRKE05LO&$8--"ETQB./>_^_+K_!ORY[#%"5RBU!QZ]# 7XV093Y*1Z,L2]\E
M!T.80>[YH.0.<QBS$7W2T1BR-/_S(*?%YT_P,= HN!05#K&Z7AJQN'+P6_$[
M!-2)5@JEQ"6<"L55(;B$+[WD/^!,%0E\D!*F'F9)IT5S@V72L=[9,K?%%5;\
M]2L 2IBRN2+*III$/A-=(NYF1B;:+%CI#'/+&ADYQ>2%1A31 /K_N T,5<);
M[ HXYW860+W%YV<T0.#URA>O*=-2--5,Z% @GY1T/!H/W$L4*_\@R&*1+/0-
M(\,ZM;>+QT,8I>F843\XRC(.(%*H'SL0WCRCUA@>L@&Y'0= =GAXR()U35+I
M'D;0L;]EK3%X<^>,F#4.3[6I3G#.&TFH1ETW7(JYP#)X49]6J-P#GX<>CIL%
MN@M>H:UY@4]*-;738W&1U(Q]^W3^)71:=.P! *'Y1%5KXZ#MP7-=A+NQ(YW^
M6]Q7(?9;<3:*QUE"9!&H#=4[2@CLQ4+ZXCY+R*HS]A9BMW6P7\1^L>WTQ_O^
MV1E8O\X^_D,??W:P5_P;X^ G*-'JXJ5B!C/M^3517!3MR&J7^]?E'OFBWNRG
M@L_#VYT'KX^1[M1P)E=*NW#04 FO:Z'FNMNB3=_$>=_)4YQ#&%\Y-X71$G</
M.58;7:-Q@D;\_65H":X,SB<17L?]E/DN^2RA*=,[;- _O%S>S B"\OQ>7(]U
MPGGPN3>#M]-+R>6*VC?#)+*4=3FXG+\TV-K@4X,EB*7)'DJV/>;/ Z\GA^[/
MN20/\(NOT[/M;\/J<6".WVFEJV4K\D07C7]_^O\?5/E1D;3E&765J8*L" 2]
M(E-R_[Z7^TID+[-$^MTF0NMFJ?^CGW4]PW#)50DM'0SXCM@ZR3I_8['\1QV'
M=<%ET<A5TCMPY[$+N%ZN_9'WRK;CNMV^8/T59NMWN-L9WO5VJYTU]/4_4$L#
M!!0    ( +J =U:Z^4)PJP8  *5)   3    97$M,C R,S S,C-?;&%B+GAM
M;,V<;6_;-A#'WQ?H=[AY;S:@LF-E*%:C:9$Y21$L;8+&W88-0R%+C$U,)@U2
MCNUO/U(/C1Q3,A6>J@!]4*2[_]U?_IW"R%;>OM\L8K@G0E+.3GK#_E$/" MY
M1-GLI+>27B!#2GL@DX!%0<P9.>EMB>R]?_?RQ=L?/ _.+BX_@0?S)%G*T6"P
M7J_[T1UEDL>K1$G*?L@7 _"\(GX\^0)_9.5&\)G$)) $%H%,B(#?5C2.1OZ1
M[P^'1[_V7Y?3! FT'D1!0D9P//#5GR/_&(9'HU]>C]3&S4<X3V483.B"E'/Y
M<BOH;)[ 3^'/D&:=<<9('),M7% 6L) &,=P6+;^"2Q;VX32.X;-.DZI/2<0]
MB?JY:DS9?R/]SU1W#R]? *C3R&2Z[Z2G3T9^+C93$?>YF*EFCXX'14KO(6.S
ME[(^3A.&;]Z\&:1'R]&2FF*5^'#PU\>KVW!.%H&G3K]ZN<*\C*0CF>Z_XF%Z
M#BT:A,H(_957A'EZES?TO>-A?R.CWCM=,#\[P93$5VH+4@\CP6-24U@?3JOW
M\OADNU3Q9),0%I%<^9LV#_.HN2!WF:J&+Y64).S/^/T@(E03XNL-3V_H#G]4
M7WP=<\7[Z50F(@B3W7JQ/D5<%#M3$R<]0])@MR$==RK"':U A(6.VCS@/X\8
MA%R];LO$2Q6+]#O!%\8N\G+<</!K/(V-;6J2U)8>;\*\+[>'O&9"96."2+X2
M"J\F+VWJYUVJ#/\4VO^^'3S4?BZMJDN()%=-^W5#\G2A,%=_DXLXF-DB^2BI
M(R3-K7/#01<D#4)(2'Y3!BWM#&0+C9:!M.W6#<=SEM!D.U9E1!!?J@OPYG>R
MM<6R(KDC/.NM\)H@%UQK!)&PS2I 7@+2&J"*. /<8NMED)OW[X;T&0]7>FXF
MJGM;DG=S.@+8V#C?/^:"Z[X.$J6%,&AE9S3QVRP3:=DK#H8W1% >G;/H3/T\
MTY3'1\D=@VFVPFN",% U"&(SFY4 50-T$31\6VC=R+%U_QB+A<]D1O4BF26?
M@H4UT>;<3I<*%49X=8S[0L&DA[M.>*@ N@32*J&-O@V+!.OF,4"^9"$72R[2
M6R6WB1J<,5^I1<IVS*.&7!^0ZA1S.YO<.L5]""SD<6=BIR"D%2$O";HFTI!\
M!U^&F7FZ.8PANJ Q^;1:3(EH-C'EO$['PV" FX^[@_]8"Y=RK0Z9/!+0V/T:
MZ+5J&@/42;"YC-1BB=[1[.;X4ZBM%.D4X4/6N$6P.]RUPKBDJU*P6PN7^U:M
M&(;@"7XP1N(TBI0!F?]W11D9-AL'HT"GHU!GB1\(=!^!2E%<_'/]5\4&Z$IP
MS;#6,:W9,*#_!"_MH.^[HN\_._1]6_3]-M#WOQ_ZDS5O#7TD&];HUWI!1'^L
M-J_%A*_9D\ OIS\'[ UV3- _A*$A_UBR)>!U&> "="%<V+$-U*%NYP(1\_3G
MX6MQ(_@]96'#VSI5&L\!^"IC)NH?Q:*A;]1MB?_LQH9"IZB&.P2M6*F;A 9^
M$,?AALLDB/^FR^;W.,T*SV$4S*9,@[ 3B38&!M66AB"K!*H4YGW+]FS4#8"U
M%\?/ &J#@@1-@-_-Z>H3@*;&^?XQI\__[>D@@9M^G]?*.)SB][GSV3_+9MU
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MI%BBKSS"$L^.W_^P7'(9[=7E%G?8QY;71^R+?0@7]_P#4$L! A0#%     @
MNH!W5@<&L!-O#P  #&4   X              ( !     &0T-S$V,S1D.&LN
M:'1M4$L! A0#%     @ NH!W5IXK>6 ]*0  FG<! !$              ( !
MFP\  &0T-S$V,S1D97@Y.3$N:'1M4$L! A0#%     @ NH!W5OV4L%Q! P
M1PL   \              ( !!SD  &5Q+3(P,C,P,S(S+GAS9%!+ 0(4 Q0
M   ( +J =U:Z^4)PJP8  *5)   3              "  74\  !E<2TR,#(S
M,#,R,U]L86(N>&UL4$L! A0#%     @ NH!W5N<A0MO>!   _BT  !,
M         ( !44,  &5Q+3(P,C,P,S(S7W!R92YX;6Q02P4&      4 !0 Z
) 0  8$@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
